Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253019 · ClinicalTrials.gov registry record
A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 321
- Enrollment target
NCT00253019: Completed study, sponsored by Emory University.
NCT00253019 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 321 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00253019 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 321 participants
- Enrollment target
Study Summary
This study will assess the continuation rates among women using oral contraceptive pills, Depo-Provera and Ortho Evra following a first trimester abortion.
Primary Outcome
We followed subjects to evaluate the continuation rates for subjects receiving oral contraceptive pills, Depo Provera and Ortho Evra.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-11 |
What the finished NCT00253019 record still lists
NCT00253019 is an observational study that tracks outcomes without assigning an intervention. The registered 321 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00253019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00253019 about?
NCT00253019 is a clinical study titled "A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods". This study will assess the continuation rates among women using oral contraceptive pills, Depo-Provera and Ortho Evra following a first trimester abortion.
What is the current status of trial NCT00253019?
This trial is currently completed. The enrollment target is 321 participants. The study started on 2004-10. Estimated completion is 2005-11.
Who is sponsoring clinical trial NCT00253019?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia